‘Important step forward’ in endometrial cancer treatment

3 minute read


The TGA expanded its approval for the use of the anti-PD-1immune therapy drug dostarlimab.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×